^
    Back
    Association details:
    Biomarker:NPM1 mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:entospletinib (GS-9973) (SYK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Combining chemotherapy with either the medication entospletinib or a placebo for adults with acute myeloid leukemia that has a nucleophosmin-1 abnormality

    Excerpt:
    ...NPM1-mutated disease documented in a local or the Sponsor's central testing facility. ...
    Trial ID:
    2021-000761-33
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML

    Excerpt:
    ...Nucleophosmin-1 (NPM1)-mutated disease documented in a local or the Sponsor's central testing facility....
    Trial ID:
    AGILITY
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    GlobeNewswire
    Title:

    Kronos Bio Announces Positive End-of-Phase 2 Meeting with FDA for Entospletinib in Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia (AML)

    Published date:
    03/04/2021
    Excerpt:
    Kronos Bio, Inc. (Nasdaq: KRON) today announced, following receipt of minutes from its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), that the company will proceed with its plan to assess measurable residual disease (MRD) negative complete response (CR) as the primary endpoint in a registrational Phase 3 trial to support potential accelerated approval of entospletinib in patients newly diagnosed with NPM1-mutated acute myeloid leukemia (AML).
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2023
    Title:

    5037 Combined Single Cell Flow Cytometry and Imaging Analyses Reveal Immunomodulatory Effects Exerted By Targeted Phospho-SYK Inhibitors with Elevated Sensitivity in NPM1 Mutated AML

    Published date:
    11/02/2023
    Excerpt:
    Differential analyses of data from flow cytometry (AML-HP-FC Cohort) and single cell imaging (AML-sc-MI Cohort) demonstrated: 1) sensitivity to ENTO and LANRA (³ 1uM) was higher in NPM1 and FLT3 mutated AML samples…